Overview

This trial is active, not recruiting.

Conditions septic arthritis, juvenile idiopathic arthritis
Treatment articular punction, salivary samples, blood sample
Sponsor University Hospital, Montpellier
Start date April 2015
End date April 2017
Trial size 30 participants
Trial identifier NCT02505828, 2014-A01561-46, 93612

Summary

The aim of this study is to find markers that could differentiate infectious and inflammatory arthritis. The investigators want to find markers by differential analysis by compare synovial fluids of septic and inflammatory arthritis. The investigators will use for this analysis, proteomics, cytokine dosage and monocyte typing by flow cytometry analysis. The investigators will use one marker or a score with biological and clinical data to discriminate arthritis of infectious and inflammatory etiology.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Intervention model single group assignment
Masking single blind (subject)
Primary purpose diagnostic
Arm
(Other)
with bacteriological identification
articular punction, salivary samples, blood sample Proteomic analysis
(Other)
beyond the ILAR (International League of Associations for Rheumatology) definition
articular punction, salivary samples, blood sample Proteomic analysis

Primary Outcomes

Measure
Qualitative analysis of new biological markers (proteic, cytokine or cellular) that discriminate inflammatory and infectious arthritis.
time frame: 1 day

Eligibility Criteria

Male or female participants from 6 months up to 18 years old.

Inclusion Criteria: - Septic arthritis with bacteriological identification - Juvenile idiopathic arthritis beyond the ILAR definition - Having acute arthritis requiring an articular draining - Child benefiting from a national insurance scheme - Collection of the consent of the parents or the legal representative Exclusion Criteria: - Contraindication in an articular draining: platelet 50 000 / mm3, Rate of prothrombins lower than 70 %, activated partial thromboplastin times (APTT)> 1,5 - Treatment by biotherapy, corticoids or other immuno suppressor in the month preceding the articular draining. - Treatment by antibiotic begun more than 24 hours before the draining.

Additional Information

Official title ARTEMIS Synovial Markers in Arthritis Childhood
Principal investigator Eric EJ JEZIORSKI, MD, PhD
Trial information was received from ClinicalTrials.gov and was last updated in July 2015.
Information provided to ClinicalTrials.gov by University Hospital, Montpellier.